Esperion's Oral Bempedoic Acid Passes First Phase III Cholesterol Test

'Study 4' results may support a label claim related to reducing inflammation – measured through the high sensitivity C-reactive protein (hsCRP) marker – down the line, the company told investors.

Arteries swelling because blood clot by fat cloged made blood flow slowly. Illustration about danger of Cholesterol.

Esperion Therapeutics Inc.'s oral, once-daily bempedoic acid delivered its first set of positive Phase III results for LDL cholesterol reduction, in a trial done in statin intolerant patients,though there still are questions about how the drug would be received by payers if it does ultimately get to the market.

Esperion plans to report results this year from all five pivotal studies in the Phase III CLEAR development program for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category